February 13, 2019
FDA warns of link between breast implants and anaplastic large cell lymphoma
Editor's Note
The Food and Drug Administration (FDA) on February 6 posted a letter that was sent to healthcare providers to increase their awareness of the association between all breast implants, regardless of filling or texture, and breast implant associated-anaplastic large cell lymphoma (BIA-ALCL).
As of September 30, 2018, the FDA has received 660 medical device reports of patients who have developed BIA-ALCL, generally within the scar capsule adjacent to the implant.
Free Daily News
- Back to Business: Budgeting for Sustainable Staffing Models in the OR
- Healthcare job gain in August offset by losses in federal government, other industries
- AHA study: HOPD Medicare patients are poorer, sicker, more rural than those seen in physician offices
- ACS, Lifesaving Technologies launch nationwide effort to expand bleeding control readiness
- Minimally invasive ICH surgery evacuates clot fast but fails to improve 6-month outcomes
- Rural hospitals face crisis under OBBBA as experts call for cohesive reform
- AMA urges health systems to act now on AI governance
- Suicide Prevention Month: Hospitals prepare for new The Joint Commission suicide prevention goal, effective 2026
- Survey: Perioperative leaders adapt to supply strain, staffing pressure, ASC growth
- Gait retraining eases knee osteoarthritis pain as effectively as medication, can delay knee surgery
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement